ACRS Stock Summary and Trading Ideas (Aclaris Therapeutics | NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.

As of April 3, 2025, ACRS stock price declined to $1.49 with 773,846 million shares trading.

ACRS has a beta of 2.20, meaning it tends to be more sensitive to market movements. ACRS has a correlation of 0.09 to the broad based SPY ETF.

ACRS has a market cap of $159.46 million. This is considered a Micro Cap stock.

Last quarter Aclaris Therapeutics reported $9 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.17.

In the last 3 years, ACRS traded as high as $18.96 and as low as $.59.

The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, VXF, IWC, DFAS, SBIO.

ACRS has outperformed the market in the last year with a price return of +22.1% while the SPY ETF gained +4.8%. However, in the short term, ACRS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -39.9% vs -7.9% return in SPY. But in the last 2 weeks, ACRS shares have fared better than the market returning -3.9% compared to SPY -5.1%.

ACRS support price is $1.47 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS shares will trade within this expected range on the day.